Clinical Trials

Explore our clinical research and data-driven insights into the performance of the Harmony™ System. From early-phase safety studies to long-term hemodynamic outcomes, our work demonstrates a commitment to evidence-based innovation in heart failure treatment.

Validated by clinical excellence

Recognized by the Transcatheter Interventional Therapeutics (TCT) Congress for groundbreaking advancements in cardiovascular therapy.

#1
Medical Innovation Award

Congestive heart failure remains one of the largest unmet needs in medicine, affecting millions of patients and healthcare systems worldwide.

6M+
Patients impacted in the US alone

Backed by global leaders in cardiovascular devices, our platform combines deep clinical science with enterprise-grade engineering.

$50M+
Strategic Investment & R&D

Recent work

Validated by clinical and commercial leaders

“The Harmony™ System represents a meaningful clinical innovation in the treatment of congestive heart failure. Its minimally invasive approach addresses one of the largest unmet needs in modern cardiovascular medicine.”
TCT Congress Selection Committee
#1 Medical Innovation Award
“EnoPace combines deep clinical science with precise engineering. Our investment underscores the clinical and commercial credibility of the Harmony™ platform as the next breakthrough in heart failure therapy.”
Strategic Investment Partner
Sorin Group
“The ability to provide neurostimulation via a catheter-based insertion is a game-changer for patient accessibility. It offers the clinical benefits of improved heart function without the trauma of open coronary surgery.”
Interventional Cardiologist
Clinical Advisory Board

Stay informed on clinical milestones.

Subscribe for real-time updates on Harmony™ System clinical trials and news.